HER2超低表达乳腺癌的临床研究进展

doi:10.3760/cma.j.cn371439-20250225-00007

摘要/Abstract

摘要：

当前的临床研究和实践表明，人表皮生长因子受体2（HER2）低表达乳腺癌患者可以从新型抗体偶联药物（ADC）治疗中获益。乳腺癌HER2超低表达是指免疫组织化学检测评分为0，且存在≤10%的浸润性肿瘤细胞显示不完整或微弱的膜染色，占乳腺癌患者的10%~15%。HER2超低表达乳腺癌患者与HER2低表达相比，其临床病理特征、对治疗的反应及预后存在一定差异，关注乳腺癌HER2基因超低表达状态并采取相应的干预措施可使该类患者获得更好的临床疗效。

关键词: 乳腺肿瘤, 基因，erbB-2, 基因表达, 抗体偶联药物

Abstract:

Current clinical research and practice have indicated that patients with low human epidermal growth factor receptor 2 （HER2） expression breast cancer can experience therapeutic advantages from treatments with novel antibody-drug conjugates （ADCs）. HER2 ultra-low expression in breast cancer is characterized by an immunohistochemical score of 0， with ≤10% of invasive tumor cells showing incomplete or faint membrane staining. This subgroup constitutes approximately 10%-15% of all breast cancer cases. In comparison to HER2-low expression， tumors with HER2 ultra-low expression display certain differences in clinicopathological characteristics， treatment responses， and prognostic outcomes. Paying attention to HER2 ultra-low expression status and taking corresponding measures can enable these patients to achieve better clinical efficacy.

Key words: Breast neoplasms, Genes， erbB-2, Gene expression, Antibody-drug conjugate

刘欣蕾, 李亚茹, 陈书宁, 唐圣豪, 秦艳, 刘彦魁, 齐晓薇. HER2超低表达乳腺癌的临床研究进展[J]. 国际肿瘤学杂志, 2026, 53(1): 53-56.

Liu Xinlei, Li Yaru, Chen Shuning, Tang Shenghao, Qin Yan, Liu Yankui, Qi Xiaowei. Research progress of HER2 ultra-low expression breast cancer[J]. Journal of International Oncology, 2026, 53(1): 53-56.

参考文献 26

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20. DOI: 10.1056/NEJMoa2203690.
[3]	Bartsch R, Berghoff AS, Furtner J, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial[J]. Nat Med, 2022, 28(9): 1840-1847. DOI: 10.1038/s41591-022-01935-8. pmid: 35941372
[4]	Jerusalem G, Park YH, Yamashita T, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis[J]. Cancer Discov, 2022, 12(12): 2754-2762. DOI: 10.1158/2159-8290.Cd-22-0837. pmid: 36255231
[5]	朱军, 黄美金, 李媛, 等. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240. DOI: 10.3760/cma.j.cn371439-20221230-00046.
[6]	Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update[J]. J Clin Oncol, 2023, 41(22): 3867-3872. DOI: 10.1200/JCO.22.02864.
[7]	刘月平, 薛卫成, 杨文涛, 等. 乳腺癌HER2低表达病理检测进展及挑战[J]. 中华病理学杂志, 2022, 51(9): 799-802. DOI: 10.3760/cma.j.cn112151-20220620-00542.
[8]	《乳腺癌HER2检测指南(2024版)》编写组. 乳腺癌HER2检测指南(2024版)[J]. 中华病理学杂志, 2024, 53(12): 1192-1202. DOI: 10.3760/cma.j.cn112151-20241009-00664.
[9]	Venetis K, Crimini E, Sajjadi E, et al. HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer[J]. Front Mol Biosci, 2022, 9: 834651. DOI: 10.3389/fmolb.2022.834651.
[10]	Wu S, Yue M, Zhang J, et al. The role of artificial intelligence in accurate interpretation of HER2 immunohistochemical scores 0 and 1+ in breast cancer[J]. Mod Pathol, 2023, 36(3): 100054. DOI: 10.1016/j.modpat.2022.100054.
[11]	Shi JJ, Zhang LQ, Geng CZ. HER-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study[J]. Front Oncol, 2023, 13: 1210314. DOI: 10.3389/fonc.2023.1210314.
[12]	Hatami E, Fanaei SM, Hasteh F, et al. 162 HER2-ultra low and HER2-null breast cancers, incidence and correlation with clinicopathologic parameters[J]. Lab Invest, 2025, 105(3 Sup): 102386. DOI: 10.1016/j.labinv.2024.102386.
[13]	Ahuja S, Khan AA, Zaheer S. Understanding the spectrum of HER2 status in breast cancer: from HER2-positive to ultra-low HER2[J]. Pathol Res Pract, 2024, 262: 155550. DOI: 10.1016/j.prp.2024.155550.
[14]	Bardia A, Hu XC, Dent R, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer[J]. N Engl J Med, 2024, 391(22): 2110-2122. DOI: 10.1056/NEJMoa2407086.
[15]	Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ⅰb study[J]. J Clin Oncol, 2020, 38(17): 1887-1896. DOI: 10.1200/jco.19.02318.
[16]	Xiao T, Ali S, Mata DGMM, et al. Antibody-drug conjugates in breast cancer: ascent to destiny and beyond—a 2023 review[J]. Curr Oncol, 2023, 30(7): 6447-6461. DOI: 10.3390/curroncol30070474.
[17]	Andrikopoulou A, Zografos E, Liontos M, et al. Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer[J]. Clin Breast Cancer, 2021, 21(3): e212-e219. DOI: 10.1016/j.clbc.2020.08.006.
[18]	Anderson Cancer Center. Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer[EB/OL]. (2025-02-10) [2025-02-12]. https://clinicaltrials.gov/study/NCT05633979?cond=HER2%20ULTRA%20LOW&term=Breast%20Cancer&rank=2.
[19]	Zhang J. Different targeted antibody-drug conjugates for HER2 ultra-low or no expression advanced breast cancer (GALAXY)[EB/OL]. (2023-06-27) [2025-02-12]. https://clinicaltrials.gov/study/NCT05824325?cond=HER2%20ULTRA%20LOW&term=Breast%20Cancer&rank=1.
[20]	Chen ZX, Jia HQ, Zhang HN, et al. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients[J]. Breast Cancer Res Treat, 2023, 202(2): 313-323. DOI: 10.1007/s10549-023-07079-8.
[21]	Tuluhong D, Li XF, Gao HY, et al. Molecular characteristics and prognosis of breast cancer patients with different level of HER2 positivity after adjuvant and neoadjuvant chemotherapy[J]. Eur J Cancer Prev, 2023, 32(4): 377-387. DOI: 10.1097/cej.0000000000000813. pmid: 37302017
[22]	Yue M, Wu S, Wang XR, et al. RT-qPCR is helpful to distinguish the clinicopathological features of HER2 immunohistochemistry 0 and 1[J]. Pathol Res Pract, 2023, 247: 154532. DOI: 10.1016/j.prp.2023.154532.
[23]	Corné J, Quillien V, Godey F, et al. Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer[J]. Mol Oncol, 2024, 18(11): 2714-2729. DOI: 10.1002/1878-0261.13592.
[24]	Morsberger L, Pallavajjala A, Long P, et al. HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry[J]. Cancer Cell Int, 2022, 22(1): 350. DOI: 10.1186/s12935-022-02761-1.
[25]	赵熙萌, 张燕香, 马同辉, 等. 下一代测序技术在癌症诊疗中的应用及研究进展[J]. 药学进展, 2023, 47(6): 404-416. DOI: 10.20053/j.issn1001-5094.2023.06.002.
[26]	Jiang C, Li M, Zheng CY, et al. Systematic analysis of factors affecting human epidermal growth factor receptor 2 interpretation consistency: staining protocols, artificial intelligence-based image standardization, and classification criteria[J]. Lab Invest, 2025, 105(6): 104134. DOI: 10.1016/j.labinv.2025.104134.